Is the Worst Over for Illumina Stock?
With shares of the gene sequencing giant Illumina (NASDAQ: ILMN) collapsing by 53% over the last three years due to a combination of a botched acquisition attempt and weakness in its core business, shareholders are doubtlessly wondering whether the stock's decline is finished, or if it's just getting started.
With the naming of a new chief technology officer (CTO) on August 9 and a new CEO on September 5, at a minimum investors can have confidence that something about the company's strategy is going to change. But it's also easy to envision a failed attempt at a turnaround.
So let's ask whether the worst is over given what we know right now.
Source Fool.com
Illumina Inc. Aktie
106,46 €
1,94 %
Überwältigendes Buy-Interesse bei Illumina Inc., mit einer hohen Anzahl von Buy- und wenigen Sell-Einschätzungen.
Eine erhebliche Steigerung um mehr als 50% ist für Illumina Inc. mit einem Kursziel von 162 € im Vergleich zum aktuellen Kurs von 106.46 € zu erwarten.
